Tazarotene


Tazarotene

drugbox
IUPAC_name = ethyl 6- [2-(4,4-dimethylthiochroman-6-yl) ethynyl] pyridine-3-carboxylate



CAS_number = 118292-40-3
ATC_prefix = D05
ATC_suffix = AX05
ATC_supplemental =
PubChem = 5381
DrugBank = APRD01246
C = 21 |H = 21 |N = 1 |O = 2 |S = 1
molecular_weight = 351.463 g/mol
bioavailability =
protein_bound = >99%
metabolism =
elimination_half-life = 19 Hours
pregnancy_category = X (U.S.)
legal_status = Prescription Only
routes_of_administration = Topical

Tazarotene (marketed as Tazorac, Avage and Zorac) is a prescription topical retinoid sold as a cream or gel. This medication is approved for treatment of psoriasis, acne, and sun damaged skin (photodamage). It is commonly sold in two concentrations: 0.05% and 0.1%.

Common side effects include worsening of acne, dry skin, itchiness, redness and in some cases extreme drying and cracking of skin. For most patients these side effects are uncomfortable but mild and decrease markedly after the first 2–4 weeks of use.

For best results dermatologists recommend applying the cream or gel once daily before bedtime after washing the face with a mild cleanser. Dermatologists recommend using a moisturizer with tazarotene so skin will not be as dry and flaky.

"There is limited evidence that tazarotene and isotretinoin benefit patients with moderate photodamage on the face: both are associated with skin irritation and erythema." Samuel M, Brooke RC, Hollis S, Griffiths CE. Interventions for photodamaged skin. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001782. [http://www.ncbi.nlm.nih.gov/pubmed/15674885?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum PubMed Link] ]

In addition to tretinoin, which has been associated with greater skin improvements with high concentrations, tazarotene and isotretinoin creams are also found to be effective for photodamage, but at the expense of skin irritation. More evidence is needed before any recommendations can be made on oral or topical polysaccharides or hydroxy acids. Evidence from one trial suggests that the effectiveness of 0.05% tretinoin, is equivalent to the effects of 0.05% and 0.1% tazarotene.

Notes


Wikimedia Foundation. 2010.

Look at other dictionaries:

  • tazarotene — n. see retinoid * * * ta·zar·o·tene (tə zarґo tēn) a prodrug that undergoes hydrolysis to a retinoid in the skin; used topically in the treatment of acne vulgaris and psoriasis …   Medical dictionary

  • tazarotene — n.; see retinoid …   The new mediacal dictionary

  • TIG1 — Tazarotene induced gene 1 (TIG1) is a protein which has been implicated as a putative tumor suppressor. It is structurally similar to the protein latexin, which has also been shown to demonstrate some tumor suppression activity (Liang et al.,… …   Wikipedia

  • RARRES1 — Retinoic acid receptor responder (tazarotene induced) 1, also known as RARRES1, is a human gene.cite web | title = Entrez Gene: RARRES1 retinoic acid receptor responder (tazarotene induced) 1| url =… …   Wikipedia

  • RARRES3 — Retinoic acid receptor responder (tazarotene induced) 3, also known as RARRES3, is a human gene.cite web | title = Entrez Gene: RARRES3 retinoic acid receptor responder (tazarotene induced) 3| url =… …   Wikipedia

  • RARRES2 — Retinoic acid receptor responder (tazarotene induced) 2, also known as RARRES2, is a human gene.cite web | title = Entrez Gene: RARRES2 retinoic acid receptor responder (tazarotene induced) 2| url =… …   Wikipedia

  • Chemerin — Retinoic acid receptor responder (tazarotene induced) 2 Identifiers Symbols RARRES2; HP10433; TIG2 External IDs …   Wikipedia

  • Acne vulgaris — This article is about a skin disease commonly found during adolescence. For other acneform skin diseases, see Acne (disambiguation). Acne vulgaris Classification and external resources …   Wikipedia

  • Isotretinoin — Systematic (IUPAC) name (13cis) …   Wikipedia

  • Tretinoin — Systematic (IUPAC) name retinoic acid …   Wikipedia


Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.